Cellebrite DI (NASDAQ:CLBT) Price Target Increased to $18.00 by Analysts at Deutsche Bank Aktiengesellschaft

Cellebrite DI (NASDAQ:CLBT) had its price target upped by Deutsche Bank Aktiengesellschaft from $15.00 to $18.00 in a research note issued to investors on Friday, Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock.

Other equities analysts have also issued reports about the stock. Lake Street Capital lifted their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a buy rating in a report on Friday. Bank of America lifted their price objective on Cellebrite DI from $13.00 to $17.00 and gave the company a buy rating in a research note on Friday. Craig Hallum increased their target price on Cellebrite DI from $16.00 to $20.00 and gave the stock a buy rating in a research note on Friday. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $14.00 to $15.00 and gave the stock an overweight rating in a research report on Wednesday, August 14th. Finally, Needham & Company LLC increased their price objective on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a buy rating in a research report on Friday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of Buy and an average price target of $17.33.

Cellebrite DI Trading Down 0.4 %

CLBT opened at $16.37 on Friday. The company has a market cap of $3.37 billion, a price-to-earnings ratio of -28.22, a price-to-earnings-growth ratio of 1.90 and a beta of 1.50. The stock has a fifty day simple moving average of $12.75 and a two-hundred day simple moving average of $11.63. Cellebrite DI has a 12-month low of $6.36 and a 12-month high of $16.89.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. Cellebrite DI had a negative net margin of 32.57% and a positive return on equity of 417.94%. The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. During the same period in the prior year, the firm earned $0.05 EPS. The company’s revenue was up 24.8% compared to the same quarter last year. On average, analysts predict that Cellebrite DI will post 0.34 EPS for the current year.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently bought and sold shares of CLBT. Parallel Advisors LLC boosted its holdings in shares of Cellebrite DI by 75.0% during the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after acquiring an additional 1,500 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its position in Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares during the period. Quarry LP bought a new position in Cellebrite DI during the fourth quarter valued at approximately $36,000. Public Employees Retirement Association of Colorado purchased a new stake in Cellebrite DI in the second quarter worth approximately $71,000. Finally, nVerses Capital LLC bought a new stake in Cellebrite DI in the 2nd quarter worth approximately $103,000. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.